Jad Othman

880 total citations
34 papers, 251 citations indexed

About

Jad Othman is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Jad Othman has authored 34 papers receiving a total of 251 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 10 papers in Genetics and 9 papers in Molecular Biology. Recurrent topics in Jad Othman's work include Acute Myeloid Leukemia Research (16 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (5 papers). Jad Othman is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (5 papers). Jad Othman collaborates with scholars based in Australia, United Kingdom and United States. Jad Othman's co-authors include Richard J. Coffey, Richard Dillon, Nicola Potter, Amanda Gilkes, Nigel H. Russell, Jelena Jovanović, Adam Ivey, Manohursingh Runglall, Ian Thomas and Sean Johnson and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Annals of Internal Medicine.

In The Last Decade

Jad Othman

30 papers receiving 246 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jad Othman Australia	8	117	53	47	47	46	34	251
Adane F. Wogu United States	8	51 0.4×	45 0.8×	27 0.6×	8 0.2×	22 0.5×	18	279
Malak Elbatarny Canada	9	188 1.6×	38 0.7×	92 2.0×	18 0.4×	15 0.3×	32	449
Muhammad H. Bashir United States	9	60 0.5×	28 0.5×	55 1.2×	7 0.1×	22 0.5×	20	314
Suresh Raghavaiah United States	7	49 0.4×	30 0.6×	42 0.9×	11 0.2×	11 0.2×	10	605
Noppacharn Uaprasert Thailand	11	159 1.4×	90 1.7×	24 0.5×	6 0.1×	16 0.3×	50	318
Laura Banov Italy	9	135 1.2×	21 0.4×	23 0.5×	4 0.1×	20 0.4×	21	234
Faris Madanat Jordan	9	87 0.7×	22 0.4×	19 0.4×	4 0.1×	61 1.3×	18	215
Leo Sekine Brazil	12	68 0.6×	22 0.4×	13 0.3×	5 0.1×	40 0.9×	44	363
D Sońta-Jakimczyk Poland	9	89 0.8×	33 0.6×	13 0.3×	6 0.1×	41 0.9×	69	291
Eileen T. Chambers United States	9	20 0.2×	12 0.2×	20 0.4×	19 0.4×	18 0.4×	25	250

Countries citing papers authored by Jad Othman

Since Specialization

Citations

This map shows the geographic impact of Jad Othman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jad Othman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jad Othman more than expected).

Fields of papers citing papers by Jad Othman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jad Othman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jad Othman. The network helps show where Jad Othman may publish in the future.

Co-authorship network of co-authors of Jad Othman

This figure shows the co-authorship network connecting the top 25 collaborators of Jad Othman. A scholar is included among the top collaborators of Jad Othman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jad Othman. Jad Othman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Russell, Nigel H., Jad Othman, Oliver Cumming, et al.. (2025). Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 -mutated AML. Blood Advances. 9(24). 6455–6466.

Levade, M, Qiang Chen, Jad Othman, et al.. (2025). Growth factor independent 1B is a metabolic regulator that exerts pleiotropic effects on platelet function. Journal of Thrombosis and Haemostasis. 23(10). 3349–3361.

Othman, Jad, Nicola Potter, Adam Ivey, et al.. (2024). Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 143(19). 1931–1936. 33 indexed citations

Loo, Sun, Nicola Potter, Adam Ivey, et al.. (2024). Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia. Blood. 144(24). 2554–2557. 4 indexed citations

Othman, Jad, Nicola Potter, Jelena Jovanović, et al.. (2024). Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19. Blood. 144(Supplement 1). 845–845.

Mason, George, et al.. (2024). Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice‐site CBL variant alongside a novel constitutional CSF3R variant. SHILAP Revista de lepidopterología. 5(2). 397–402. 1 indexed citations

Abadir, Edward, Jad Othman, John Kwan, et al.. (2023). Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from Australia and New Zealand Transplant and Cellular Therapies. Transplantation and Cellular Therapy. 30(3). 334.e1–334.e7. 2 indexed citations

Russell, Nigel H., Jad Othman, Richard Dillon, et al.. (2023). S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL. HemaSphere. 7(S3). e252478c–e252478c. 1 indexed citations

Othman, Jad, et al.. (2022). Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients. Leukemia & lymphoma. 63(14). 3418–3425. 6 indexed citations

10.

Loo, Sun, Richard Dillon, Adam Ivey, et al.. (2022). Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 140(22). 2407–2411. 42 indexed citations

11.

Russell, Nigel H., Charlotte S. Wilhelm-Benartzi, Steven Knapper, et al.. (2022). FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial. Blood. 140(Supplement 1). 526–528. 4 indexed citations

12.

Russell, Nigel H., Steven Knapper, Ulrik Malthe Overgaard, et al.. (2022). S128: A RANDOMISED COMPARISON OF CPX-351 AND FLAG-IDA IN HIGH RISK ACUTE MYELOID LEUKAEMIA. RESULTS FROM THE NCRI AML19 TRIAL. HemaSphere. 6. 29–30. 1 indexed citations

13.

Lindsay, Julian, Jad Othman, Sebastiaan J. van Hal, et al.. (2021). SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation. Open Forum Infectious Diseases. 8(11). ofab502–ofab502. 11 indexed citations

14.

Lindsay, Julian, Jad Othman, Michelle K. Yong, et al.. (2021). Dynamics of Epstein–Barr virus on post‐transplant lymphoproliferative disorders after antithymocyte globulin‐conditioned allogeneic hematopoietic cell transplant. Transplant Infectious Disease. 23(5). e13719–e13719. 7 indexed citations

15.

Lindsay, Julian, Jad Othman, Ian Kerridge, et al.. (2020). Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre‐transplant predictors of survival, reactivation, and spontaneous clearance. Transplant Infectious Disease. 23(3). e13548–e13548. 8 indexed citations

16.

Othman, Jad, Christopher Arthur, Keith Fay, et al.. (2020). Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma. Bone Marrow Transplantation. 55(7). 1460–1463. 3 indexed citations

17.

Othman, Jad, Emma Verner, Constantine S. Tam, et al.. (2017). Autoimmune hemolytic anemia and hemolytic transfusion reactions in two patients with Waldenstrom macroglobulinemia treated with combination BTK inhibitor and PD-1 inhibitor. Blood. 130. 5153–5153. 1 indexed citations

18.

Sughrue, Michael E., Phillip A. Bonney, Joshua D. Burks, et al.. (2017). Multilobar Insular-Involving Gliomas: Results with Hyperaggressive Resection. Cureus. 9(8). e1623–e1623. 9 indexed citations

19.

Sughrue, Michael E., Jad Othman, Steven A. Mills, et al.. (2015). Keyhole transsylvian resection of infiltrative insular gliomas: technique and anatomic results. Turkish Neurosurgery. 26(4). 475–83. 5 indexed citations

20.

Coffey, Richard J., et al.. (1995). Extending the Application of Critical Path Methods. Quality Management in Health Care. 3(2). 14–29. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact